IDEXX Laboratories (NASDAQ:IDXX) Releases Earnings Results, Beats Expectations By $0.33 EPS

IDEXX Laboratories (NASDAQ:IDXX) posted its quarterly earnings results on Tuesday. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33, Zacks reports. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same period last year, the firm posted $3.50 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories updated its FY 2026 guidance to 14.690-14.940 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• Strong second-quarter performance: Revenue grew 10% reported and 9% organically, while comparable EPS increased 15% to $4.27. IDEXX raised its full-year revenue outlook to $4.70 billion–$4.745 billion and EPS outlook to $14.69–$14.94.
• CAG Diagnostics recurring revenue grew 10.3% organically, including nearly 10% growth in the U.S. and nearly 12% internationally, driven by testing volumes, customer additions, instrument placements and higher utilization.
• Innovation momentum remained strong, with 1,602 inVue Dx placements in the quarter and 2,700 year-to-date, keeping the company on pace for its 5,500-unit annual goal. The controlled rollout of inVue Dx FNA is expanding in the third quarter, with broad availability planned by year-end, while Cancer Dx surpassed 10,000 ordering clinics.
• U.S. same-store clinical visits declined 1.3%, with wellness visits down nearly 3%, and IDEXX expects a similar approximately 1.5% decline in the second half. Management cited consumer economic pressure and slower pet adoption trends as ongoing constraints.
• Comparable operating margin expanded 110 basis points to approximately 35% in the second quarter, but IDEXX plans additional commercial, R&D, IT and AI investments in the second half. The company also expects foreign exchange to create a $15 million full-year revenue headwind, partly offsetting operational improvements.

IDEXX Laboratories Trading Down 0.1%

Shares of NASDAQ:IDXX traded down $0.79 during midday trading on Thursday, reaching $583.99. 177,867 shares of the company’s stock were exchanged, compared to its average volume of 585,611. The firm’s 50 day simple moving average is $558.83 and its two-hundred day simple moving average is $586.67. IDEXX Laboratories has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.82. The stock has a market cap of $46.07 billion, a price-to-earnings ratio of 41.06, a P/E/G ratio of 3.21 and a beta of 1.54.

Institutional Trading of IDEXX Laboratories

Institutional investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $265,000. DV Equities LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $76,000. Greenline Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $68,000. Navera Investment Management Ltd. purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $139,000. Finally, Meeder Asset Management Inc. raised its stake in IDEXX Laboratories by 563.2% during the 4th quarter. Meeder Asset Management Inc. now owns 126 shares of the company’s stock worth $85,000 after acquiring an additional 107 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. UBS Group boosted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday. Citigroup lifted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $756.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.